Management

主要研究者将对该计划的科学管理负有全面和最终责任，并将采取行动 与项目领导人（PL）和核心领导人（CL）协商， 以马克思PI在管理大型研究和用户设施方面具有相当丰富的经验 计划，以及以前的P01补助金的管理。佛罗里达州立大学，作为主要的 申请机构将有责任建立和维持适当的行政 和财务监督。每个合作伙伴都有相应的行政和财政支助。 机构职能体系 团队机构将从佛罗里达州立大学获得分包合同。分包合同付款将 在审查研究者提交的年度工作计划后，由PI批准，核心或 项目领导批准。分包合同将在每年两次的面对面会议上进行年度审查 团队和执行委员会（由项目和核心领导人组成）的会议。私家侦探会有 与外部咨询委员会进行此类咨询和额外讨论后的责任 成员与NIAID的适当计划官员讨论任何调整的金额， 各种分包合同，以最大限度地提高该计划的进展，实现其目标。除了面对面 会议执行委员会将通过电话会议（视频与PowerPoint时， 有益），项目和核心领导人还将定期通过电话会议与他们的个人 项目和核心团队以及会议记录将提交给PI。 该计划还将建立一个外部咨询委员会，该委员会将拥有结核病方面的各种专业知识 和药物开发领域。在选择委员会成员时，我们的意图是扩大 专业知识，特别是在潜在的药物开发方向，这样我们就可以责成委员会， 评估我们在确定潜在药物靶点方面的进展。我们希望每一个成员 委员会每年在我们的一次面对面会议上与该计划会面。由于有两个 我们希望每一次会议都有几位委员参加。他们将被要求提交一份简报， 每次会议后向PI报告。这些报告将成为NIAID年度报告的一部分。 PI全权负责向NIAID报告科学进展和目标。PL和CL 有责任在NIAID截止日期前两周向PI提交年度报告， 在第二届年度计划会议之后。佛罗里达州立大学有责任报告 每年一次，关于该计划的财务状况

The PI will have overall and final responsibility for the scientific management of the Program and will act in consultation with the Project Leaders (PLs) and Core Leaders (CLs) who will form an Executive Committee. The PI has considerable experience in the management of large research and user facility programs, as well as the management of a previous P01 grant. Florida State University, as the primary applicant institution will have the responsibility for establishing and maintaining the appropriate administrative and financial oversight. Corresponding administrative and financial support exists at each of the collaborating institutions. Team institutions will receive subcontracts from Florida State University. Subcontract payments will be approved by the PI following review of an annual work plan submitted by the investigators with the Core or Project leaders approval. Subcontracts will be reviewed annually at one of the biannual face-to-face meetings of the Team and Executive Committee (composed of Project and Core Leaders). The PI will have the responsibility following such consultation and additional discussion with External Advisory Committee members to discuss with the appropriate Program officer at NIAID any adjustment in the amount of the various subcontracts to maximize the Program's progress towards its aims. In addition to the face-to-face meeting the Executive committee will meet every month by conference call (video with powerpoint when beneficial), The Project and Core Leaders will also meet regularly by conference call with their individual project and core teams and minutes will be submitted to the PI. The Program will also establish an External Advisory Committee that will have diverse expertise in the TB and drug development arenas. In choosing committee members it will be our intent to expand the base of expertise, especially in the direction of potential drug development, so that we can charge the committee to assess our progress towards the goal of characterizing potential drug targets. We expect each member of the committee to meet annually with the Program in one of our face-to-face meetings. Since there are two of these we hope to have several committee members at each meeting. They will be asked to submit a brief report to the PI following each meeting. These reports will be part of the Annual Report to NIAID. The PI has full responsibility for reporting to NIAID on scientific progress and goals. The PLs and CLs have the responsibility to submit an annual report to the PI two weeks before the NIAID due date and following the second annual Program meeting. Florida State University has responsibility for reporting annually on the financial status of the Program